Our mission is to combine the regional strengths of Singapore, China and Germany (SCG) and translate state-of-the-art scientific and clinical advances to design and develop novel immunotherapies.
We are a leading global biological company specializing in TCR-T technology for the treatment of pathogen induced solid tumors. The company's core products cover: hepatitis B virus-related liver cancer, Helicobacter pylori-related gastric cancer, HPV virus-induced cervical cancer and others.
